These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28540330)

  • 1. Targeting RET-rearranged lung cancers with multikinase inhibitors.
    Sabari JK; Siau ED; Drilon A
    Oncoscience; 2017 Mar; 4(3-4):23-24. PubMed ID: 28540330
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
    Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
    Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
    Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
    Front Oncol; 2021; 11():704084. PubMed ID: 34497761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
    Drilon A; Lin JJ; Filleron T; Ni A; Milia J; Bergagnini I; Hatzoglou V; Velcheti V; Offin M; Li B; Carbone DP; Besse B; Mok T; Awad MM; Wolf J; Owen D; Camidge DR; Riely GJ; Peled N; Kris MG; Mazieres J; Gainor JF; Gautschi O
    J Thorac Oncol; 2018 Oct; 13(10):1595-1601. PubMed ID: 30017832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions.
    Ackermann CJ; Stock G; Tay R; Dawod M; Gomes F; Califano R
    Onco Targets Ther; 2019; 12():7857-7864. PubMed ID: 31576143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
    Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
    J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 10. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer.
    O'Leary C; Xu W; Pavlakis N; Richard D; O'Byrne K
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31058838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: identification of
    Ma J; Wang B; Meng E; Meng X
    Gland Surg; 2021 Sep; 10(9):2874-2879. PubMed ID: 34733735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
    Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
    Front Oncol; 2014; 4():58. PubMed ID: 24744988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
    Subbiah V; Berry J; Roxas M; Guha-Thakurta N; Subbiah IM; Ali SM; McMahon C; Miller V; Cascone T; Pai S; Tang Z; Heymach JV
    Lung Cancer; 2015 Jul; 89(1):76-9. PubMed ID: 25982012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation.
    Hayashi T; Odintsov I; Smith RS; Ishizawa K; Liu AJW; Delasos L; Kurzatkowski C; Tai H; Gladstone E; Vojnic M; Kohsaka S; Suzawa K; Liu Z; Kunte S; Mattar MS; Khodos I; Davare MA; Drilon A; Cheng E; Stanchina E; Ladanyi M; Somwar R
    Dis Model Mech; 2020 Dec; 14(2):. PubMed ID: 33318047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.